Lung cancer screening is currently based only on low-dose CT scans; however, novel, more accessible methods that might improve uptake and adherence are eagerly awaited. New liquid biopsy approaches promise to revolutionize cancer screening. Herein, we discuss the opportunities and challenges associated with two such novel assays.
References
Shieh, Y. & Bohnenkamp, M. Low-dose CT scan for lung cancer screening: clinical and coding considerations. Chest 152, 204–209 (2017).
Okereke, I. C., Nishi, S., Zhou, J. & Goodwin, J. S. Trends in lung cancer screening in the United States, 2016–2017. J. Thorac. Dis. 11, 873–881 (2019).
Rolfo, C. et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13, 1248–1268 (2018).
Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018).
Russo, A. et al. Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev. Mol. Diagn. 19, 1099–1108 (2019).
Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245–251 (2020).
Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745–759 (2020).
Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science https://doi.org/10.1126/science.abb9601 (2020).
Sozzi, G. et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32, 768–773 (2014).
Zhang, L. et al. A high-performing plasma metabolite panel for early-stage lung cancer detection. Cancers (Basel) 12, E622 (2020).
Acknowledgements
We thank Umberto Malapelle and Diego de Miguel Perez for their helpful suggestions during manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.R. has received speakers’ bureau from AstraZeneca and MSD, a research grant from the Lung Cancer Research Foundation–Pfizer, and research support from Guardant Health and Biomark; has an advisory board role with ARCHER, Inivata and Merck Serono; and has consulted for Mylan and Oncopass. A.R declares no competing interests.
Rights and permissions
About this article
Cite this article
Rolfo, C., Russo, A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 17, 523–524 (2020). https://doi.org/10.1038/s41571-020-0393-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-0393-z
- Springer Nature Limited
This article is cited by
-
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
British Journal of Cancer (2024)
-
Plasticity of circulating tumor cells in small cell lung cancer
Scientific Reports (2023)
-
Current lung cancer screening guidelines may miss high-risk population: a real-world study
BMC Cancer (2021)